An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Trial Profile

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 May 2018

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 22 May 2018 Status changed from recruiting to suspended.
    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top